Immunity and Breast Cancer: Focus on Eosinophils

[en] The role of eosinophils, a cell type involved in the immune response to parasitic infections and allergies, has been investigated in different cancer types, in both tumor tissue and at the circulating level. Most studies showed a role mainly in conjunction with immunotherapy in melanomas and lung tumors, while few data are available in breast cancer. In this review, we summarize literature data on breast cancer, showing a prognostic role of circulating eosinophil counts as well as of the presence of tumor tissue infiltration by eosinophils. In particular, some studies showed an association between a higher circulating eosinophil count and a good prognosis, as well as an association with response to neoadjuvant chemotherapy in hormone receptor-negative/HER2-positive and in triple negative breast cancer. Several mechanistic studies have also been conducted in in vivo models, but the exact mechanism by which eosinophils act in the presence of breast cancer is still unknown. Further studies on this subject are desirable, in order to understand their role at the cellular level, identify related biomarkers and/or possibly search for new therapeutic targets.

Disciplines :

Oncology

Author, co-author :

Poncin, Aurélie ; Centre Hospitalier Universitaire de Liège - CHU > Département des sciences cliniques > Service d'oncologie médicale

Onesti, Concetta Elisa

JOSSE, Claire ; Centre Hospitalier Universitaire de Liège - CHU > Département des sciences cliniques > Service d'oncologie médicale

Boulet, Delphine

Thiry, Jérôme

Bours, Vincent ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Génétique humaine

Jerusalem, Guy ; Université de Liège - ULiège > Département des sciences cliniques > Oncologie

Language :

English

Title :

Immunity and Breast Cancer: Focus on Eosinophils

Publication date :

August 2021

Journal title :

Biomedicines

eISSN :

2227-9059

Publisher :

MDPI AG, Switzerland

Volume :

Issue :

Pages :

1087

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://www.mdpi.com/2227-9059/9/9/1087

Available on ORBi :

since 07 September 2021

Statistics

Number of views

170 (13 by ULiège)

Number of downloads

215 (12 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, A.L.; Jemal, A. Global cancer statistics 2018, GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394-424.
Loibl, S.; Schneeweiss, A.; Huober, J.B.; Braun, M.; Rey, J.; Blohmer, J.U.; Furlanetto, J.; Zahm, D.M.; Hanusch, C.; Thomalla, J.; et al. Durvalumab improves long-term outcome in TNBC: Results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). J. Clin. Oncol. 2021, 39 (Suppl. 15), 506.
Mittal, D.; Gubin, M.M.; Schreiber, R.D.; Smyth, M.J. New insights into cancer immunoediting and its three component phases—Elimination, equilibrium and escape. Curr. Opin. Immunol. 2014, 27, 16-25.
Ono, M.; Tsuda, H.; Shimizu, C.; Yamamoto, S.; Shibata, T.; Yamamoto, H.; Hirata, T.; Yonemori, K.; Ando, M.; Tamura, K.; et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res. Treat. 2012, 132, 793-805.
Hwang, H.W.; Jung, H.; Hyeon, J.; Park, Y.H.; Ahn, J.S.; Im, Y.; Nam, S.J.; Kim, S.W.; Lee, J.E.; Yu, J.; et al. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. Breast Cancer Res. Treat. 2019, 173, 255-266.
Stanton, S.E.; Disis, M.L. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J. Immunother. Cancer 2016, 4, 59.
Salgado, R.; Denkert, C.; Campbell, C.; Savas, P.; Nuciforo, P.; Aura, C.; de Azambuja, E.; Eidtmann, H.; Ellis, C.E.; Baselga, J.; et al. Tumor-Infiltrating Lymphocytes and Associations with Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated with Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncol. 2015, 1, 448-454.
Denkert, C.; Loibl, S.; Noske, A.; Roller, M.; Müller, B.M.; Komor, M.; Budczies, J.; Darb-Esfahani, S.; Kronenwett, R.; Hanusch, C.; et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 2010, 28, 105-113.
Denkert, C.; von Minckwitz, G.; Brase, J.C.; Sinn, B.V.; Gade, S.; Kronenwett, R.; Pfitzner, B.M.; Salat, C.; Loi, S.; Schmitt, W.D.; et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J. Clin. Oncol. 2015, 33, 983-991.
Stanton, S.E.; Adams, S.; Disis, M.L. Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. JAMA Oncol. 2016, 2, 1354-1360.
Khoury, T.; Nagrale, V.; Opyrchal, M.; Peng, X.; Wang, D.; Yao, S. Prognostic Significance of Stromal Versus Intratumoral Infiltrating Lymphocytes in Different Subtypes of Breast Cancer Treated with Cytotoxic Neoadjuvant Chemotherapy. Appl. Immunohistochem. Mol. Morphol. 2018, 26, 523-532.
Peng, G.L.; Li, L.; Guo, Y.W.; Yu, P.; Yin, X.; Wang, S.; Liu, C. CD8(+) cytotoxic and FoxP3(+) regulatory T lymphocytes serve as prognostic factors in breast cancer. Am. J. Transl. Res. 2019, 11, 5039-5053.
Ladoire, S.; Arnould, L.; Apetoh, L.; Coudert, B.; Martin, F.; Chauffert, B.; Fumoleau, P.; Ghiringhelli, F. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin. Cancer Res. 2008, 14, 2413-2420.
Wagner, J.; Rapsomaniki, M.A.; Chevrier, S.; Anzeneder, T.; Langwieder, C.; Dykgers, A.; Rees, M.; Ramaswamy, A.; Muenst, S.; Soysal, S.D.; et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell 2019, 177, 1330-1345.e18.
Salemme, V.; Centonze, G.; Cavallo, F.; Defilippi, P.; Conti, L. The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. Front. Oncol. 2021, 11, 610303.
Ali, H.R.; Chlon, L.; Pharoah, P.D.; Markowetz, F.; Caldas, C. Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study. PLoS Med. 2016, 13, e1002194.
Papatestas, A.E.; Lesnick, G.J.; Genkins, G.; Aufses Jr, A.H. The prognostic significance of peripheral lymphocyte counts in patients with breast carcinoma. Cancer 1976, 37, 164-168.
Vicente Conesa, M.A.; Garcia-Martinez, E.; Gonzalez Billalabeitia, E.; Benito, A.; Garcia Garcia, T.; Vicente Garcia, V.; Ayala de la Peña, F. Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy. Breast 2012, 21, 468-474.
Ownby, H.E.; Roi, L.D.; Isenberg, R.R.; Brennan, M.J. Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer. Cancer 1983, 52, 126-130.
Pattison, C.W.; Woods, K.L.; Morrison, J.M. Lymphocytopenia as an independent predictor of early recurrence in breast cancer. Br. J. Cancer 1987, 55, 75-76.
Koh, C.H.; Bhoo-Pathy, N.; Ng, K.L.; Jabir, R.S.; Tan, G.; See, M.; Jamaris, S.; Taib, N.A. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br. J. Cancer 2015, 113, 150-158.
Simon, S.C.S.; Utikal, J.; Umansky, V. Opposing roles of eosinophils in cancer. Cancer Immunol. Immunother. 2019, 68, 823-833.
Marichal, T.; Mesnil, C.; Bureau, F. Homeostatic Eosinophils: Characteristics and Functions. Front. Med. 2017, 4, 101.
Lowe, D.; Jorizzo, J.; Hutt, M.S. Tumour-associated eosinophilia: A review. J. Clin. Pathol. 1981, 34, 1343-1348.
Galdiero, M.R.; Varricchi, G.; Seaf, M.; Marone, G.; Levi-Shaffer, F.; Marone, G. Bidirectional Mast Cell-Eosinophil Interactions in Inflammatory Disorders and Cancer. Front. Med. 2017, 4, 103.
Davis, B.P.; Rothenberg, M.E. Eosinophils and cancer. Cancer Immunol. Res. 2014, 2, 1-8.
Gatault, S.; Legrand, F.; Delbeke, M.; Loiseau, S.; Capron, M. Involvement of eosinophils in the anti-tumor response. Cancer Immunol. Immunother. 2012, 61, 1527-1534.
Drissen, R.; Buza-Vidas, N.; Woll, P.; Thongjuea, S.; Gambardella, A.; Giustacchini, A.; Mancini, E.; Zriwil, A.; Lutteropp, M.; Grover, A.; et al. Distinct myeloid progenitor-differentiation pathways identified through single-cell RNA sequencing. Nat. Immunol. 2016, 17, 666-676.
Reichman, H.; Karo-Atar, D.; Munitz, A. Emerging Roles for Eosinophils in the Tumor Microenvironment. Trends Cancer 2016, 2, 664-675.
Sakkal, S.; Miller, S.; Apostolopoulos, V.; Nurgali, K. Eosinophils in Cancer: Favourable or Unfavourable? Curr. Med. Chem. 2016, 23, 650-666.
Yousefi, S.; Simon, D.; Stojkov, D.; Karsonova, A.; Karaulov, A.; Simon, H. In vivo evidence for extracellular DNA trap formation. Cell Death Dis. 2020, 11, 300.
Grisaru-Tal, S.; Itan, M.; Klion, A.D.; Munitz, A. A new dawn for eosinophils in the tumour microenvironment. Nat. Rev. Cancer 2020, 20, 594-607.
Mattei, F.; Andreoni, S.; Manone, G.; Gambardella, A.R.; Loffredo, S.; Varricchi, G.; Schiavoni, G. Eosinophils in the Tumor Microenvironment. Adv. Exp. Med. Biol. 2020, 1273, 1-28. [PubMed]
Carretero, R.; Sektioglu, I.M.; Garbi, N.; Salgado, O.C.; Beckhove, P.; Hämmerling, G.J. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat. Immunol. 2015, 16, 609-617.
Hollande, C.; Boussier, J.; Ziai, J.; Nozawa, T.; Bondet, V.; Phung, W.; Lu, B.; Darragh Duffy, D.; Paradis, V.; Mallet, V.; et al. Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth. Nat. Immunol. 2019, 20, 257-264.
Kienzl, M.; Hasenoehrl, C.; Valadez-Cosmes, P.; Maitz, K.; Sarsembayeva, A.; Sturm, E.; Heinemann, A.; Kargl, J.; Schicho, R. IL-33 reduces tumor growth in models of colorectal cancer with the help of eosinophils. Oncoimmunology 2020, 9, 1776059.
Tamura, N.; Ishii, N.; Nakazawa, M.; Nagoya, M.; Yoshinari, M.; Amano, T.; Nakazima, H.; Minami, M. Requirement of CD80 and CD86 molecules for antigen presentation by eosinophils. Scand J. Immunol. 1996, 44, 229-238.
Mattes, J.; Hulett, M.; Xie, W.; Hogan, S.; Rothenberg, M.E.; Foster, P.; Parish, C. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: An eotaxin and STAT6-dependent process. J. Exp. Med. 2003, 197, 387-393.
Zheng, X.; Zhang, N.; Qian, L.; Wang, X.; Fan, P.; Kuai, J.; Lin, S.; Liu, C.; Jiang, W.; Qin, S.; et al. CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils. Int. J. Cancer 2020, 146, 1730-1740.
Arnold, I.C.; Artola-Boran, M.; Gurtner, A.; Bertram, K.; Bauer, M.; Frangez, Z.; Becher, B.; Kopf, M.; Yousefi, S.; Simon, H.; et al. The GM-CSF-IRF5 signaling axis in eosinophils promotes antitumor immunity through activation of type 1 T cell responses. J. Exp. Med. 2020, 217, e20190706.
Jacquelot, N.; Seillet, C.; Wang, M.; Pizzolla, A.; Yang Liao, Y.; Hediyeh-Zadeh, S.; Grisaru-Tal, S.; Louis, C.; Huang, O.; Schreuder, J.; et al. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nat. Immunol. 2021, 22, 851-864.
Lai, W.; Xie, H.; Liu, Y.; Zheng, F.; Zhang, Y.; Lei, Q.; Lv, L.; Dong, J.; Song, J.; Gao, X.; et al. Human pluripotent stem cell-derived eosinophils reveal potent cytotoxicity against solid tumors. Stem Cell Rep. 2021, 16, 1697-1704.
Cheng, J.N.; Luo, W.; Sun, C.; Jin, Z.; Zeng, X.; Alexander, P.B.; Gong, Z.; Xia, X.; Ding, X.; Xu, S.; et al. Radiation-induced eosinophils improve cytotoxic T lymphocyte recruitment and response to immunotherapy. Sci. Adv. 2021, 7, eabc7609.
Noffz, G.; Qin, Z.; Kopf, M.; Blankenstein, T. Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors. J. Immunol. 1998, 160, 345-350.
Hu, G.; Wang, S.; Zhong, K.; XU, F.; Huang, L.; Chen, W.; Cheng, P. Tumor-associated tissue eosinophilia predicts favorable clinical outcome in solid tumors: A meta-analysis. BMC Cancer 2020, 20, 454.
Alrawi, S.J.; Tan, D.; Stoler, D.L.; Dayton, M.; Anderson, G.R.; Mojica, P.; Douglas, W.; Hicks Jr, W.; Rigual, N.; Loree, T. Tissue eosinophilic infiltration: A useful marker for assessing stromal invasion, survival and locoregional recurrence in head and neck squamous neoplasia. Cancer J. 2005, 11, 217-225.
De Paz, D.; Chang, K.P.; Kao, H.K.; Lao, W.W.; Huang, Y.; Chang, Y.; Huang, Y. Clinical Implications of Tumor-Associated Tissue Eosinophilia in Tongue Squamous Cell Carcinoma. Laryngoscope 2019, 129, 1123-1129.
Oliveira, D.T.; Biassi, T.P.; Faustino, S.E.; Carvalho, A.L.; Landman, G.; Kowalski, L.P. Eosinophils may predict occult lymph node metastasis in early oral cancer. Clin. Oral. Investig. 2012, 16, 1523-1528.
van Driel, W.J.; Hogendoorn, P.C.; Jansen, F.W.; Zwinderman, A.H.; Trimbos, J.B.; Fleuren, G.J. Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response. Hum. Pathol. 1996, 27, 904-911.
Mascitti, M.; Togni, L.; Rubini, C.; Troiano, G.; Lo Muzio, L.; Santarelli, A. Tumour-associated tissue eosinophilia (TATE) in oral squamous cell carcinoma: A comprehensive review. Histol. Histopathol. 2021, 36, 113-122.
Samoszuk, M.K.; Nguyen, V.; Gluzman, I.; Pham, J.H. Occult deposition of eosinophil peroxidase in a subset of human breast carcinomas. Am. J. Pathol. 1996, 148, 701-706. [PubMed]
Chouliaras, K.; Tokumaru, Y.; Asaoka, M.; Oshi, M.; Attwood, K.M.; Yoshida, K.; Ishikawa, T.; Takabe, K. Prevalence and clinical relevance of tumor-associated tissue eosinophilia (TATE) in breast cancer. Surgery 2020, 169, 1234-1239.
Grisaru-Tal, S.; Itan, M.; Grass, D.G.; Torres-Roca, J.; Eschrich, S.A.; Gordon, Y.; Dolitzk, A.; Hazut, I.; Avlas, S.; Jacobsen, E.A.; et al. Primary tumors from mucosal barrier organs drive unique eosinophil infiltration patterns and clinical associations. Oncoimmunology 2020, 10, 1859732.
Voorwerk, L.; Garner, H.; Blomberg, O.S.; Spagnuolo, L.; Chalabi, M.; van Dyk, E.; Isaeva, O.I.; Bakker, N.; Klaver, C.; Duijst, M.; et al. LBA10 Critical role of eosinophils during response to immune checkpoint blockade in breast cancer and other cancer types. Ann. Oncology. 2020, 31, S1142.
Maeda, T.; Kitazoe, M.; Tada, H.; de Llorens, R.; Salomon, D.S.; Ueda, M.; Yamada, H.; Seno, M. Growth inhibition of mammalian cells by eosinophil cationic protein. Eur. J. Biochem. 2002, 269, 307-316.
Furbert-Harris, P.M.; Laniyan, I.; Harris, D.; Dunston, G.M.; Vaughn, T.; Abdelnaby, A.; Parish-Gause, D.; Oredipe, O.A. Activated eosinophils infiltrate MCF-7 breast multicellular tumor spheroids. Anticancer Res. 2003, 23, 71-78.
Qi, L.; Zhang, Q.; Miao, Y.; Kang, W.; Tian, Z.; Xu, D.; Xiao, W.; Fang, F. Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development. Int. J. Cancer 2020, 146, 1421-1434.
Benatar, T.; Cao, M.Y.; Lee, Y.; Lightfoot, J.; Feng, N.; Gu, X.; Lee, V.; Jin, H.; Wang, M.; Wright, J.A.; et al. IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo. Cancer Immunol. Immunother. 2010, 59, 805-817.
Jovanovic, I.P.; Pejnovic, N.N.; Radosavljevic, G.D.; Pantic, J.M.; Milovanovic, M.Z.; Arsenijevic, N.N.; Lukic, M.L. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int. J. Cancer 2014, 134, 1669-1682.
Xiao, P.; Wan, X.; Cui, B.; Liu, Y.; Qiu, C.; Rong, J.; Zheng, M.; Song, Y.; Chen, L.; He, J.; et al. Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells. Oncoimmunology 2016, 5, e1063772.
Shani, O.; Vorobyov, T.; Monteran, L.; Dor Lavie, D.; Cohen, N.; Raz, Y.; Tsarfaty, G.; Avivi, C.; Barshack, I.; Erez, N. Fibroblast-Derived IL33 Facilitates Breast Cancer Metastasis by Modifying the Immune Microenvironment and Driving Type 2 Immunity. Cancer Res. 2020, 80, 5317-5329.
Panagopoulos, V.; Leach, D.A.; Zinonos, I.; Ponomarev, V.; Licari, G.; Liapis, V.; Ingman, W.I.; Anderson, P.; DeNichilo, M.O.; Evdokiou, A. Inflammatory peroxidases promote breast cancer progression in mice via regulation of the tumour microenvironment. Int. J. Oncol. 2017, 50, 1191-1200.
Delyon, J.; Mateus, C.; Lefeuvre, D.; Lanoy, E.; Zitvogel, L.; Chaput, N.; Roy, S.; Eggermont, A.M.M.; Routier, E.; Robert, C. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: An early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann. Oncol. 2013, 24, 1697-1703.
Ferrucci, P.F.; Gandini, S.; Cocorocchio, E.; Pala, L.; Baldini, F.; Mosconi, M.; Antonini Cappellini, G.C.; Albertazzi, E.; Martinoli, C. Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma. Oncotarget 2017, 8, 79809-79815.
Weide, B.; Martens, A.; Hassel, J.C.; Berking, C.; Postow, M.A.; Bisschop, K.; Simeone, E.; Johanna Mangana, J.; Schilling, B.; Di Giacomo, A.M.; et al. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clin. Cancer Res. 2016, 22, 5487-5496.
Sibille, A.; Henket, M.; Corhay, J.L.; Louis, R.; Duysinx, B. Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels. Acta Oncol. 2020, 59, 257-259.
Temiz, M.Z.; Colakerol, A.; Ulus, I.; Kilic, E.; Paslanmaz, F.; Sahin, S.; Yuruk, E.; Kandirali, E.; Semercioz, A.; Muslumanoglu, A.Y. Prediction of non-muscle-invasive bladder cancer recurrence during intravesical BCG immunotherapy by use of peripheral blood eosinophil count and percentage: A preliminary report. Cancer Immunol. Immunother. 2021, 70, 245-252.
Moreira, A.; Erdmann, M.; Uslu, U.; Vass, V.; Schuler, G.; Schuler-Thurner, B. Blood Eosinophilia is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA. Pharmaceutics 2020, 12, 210.
Sheng, L.; Chen, X.; Wang, Q.; Lyu, S.; Li, P. Interferon-α2b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell vaccines. Biomed. Pharmacother. Fr. 2020, 125, 109966.
Verhaart, S.L.; Abu-Ghanem, Y.; Mulder, S.F.; Oosting, S.; Van Der Veldt, A.; Osanto, S.; Aarts, M.J.B.; Houtsma, D.; Peters, F.P.J.; Groenewegen, G.; et al. Real-world Data of Nivolumab for Patients with Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers. Clin. Genitourin. Cancer 2021, 19, e1-e274.
Gündüz, S.; Göksu, S.S.; Arslan, D.; Murat Tatli, A.; Uysal, M.; Gündüz, U.R.; Sevinç, M.M.; Coşkun, H.S.; Bozcuk, H.; Mutlu, H.; et al. Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab. Mol. Clin. Oncol. 2015, 3, 1109-1112.
Onesti, C.E.; Josse, C.; Poncin, A.; Frères, P.; Poulet, C.; Bours, V.; Jerusalem, G. Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment. Oncotarget 2018, 9, 33719-33733.
Onesti, C.E.; Josse, C.; Boulet, D.; Thiry, J.; Beaumecker, B.; Bours, V.; Jerusalem, G. Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse. Oncoimmunology 2020, 9, 1761176.
Zenan, H.; Zixiong, L.; Zhicheng, Y.; Mei, H.; Xiongbin, Y.; Tiantian, W.; Min, D.; Renbin, L.; Changchang, J. Clinical prognostic evaluation of immunocytes in different molecular subtypes of breast cancer. J. Cell Physiol. 2019, 234, 20584-20602.
Takahashi, M.; Takahashi, K.; Matsumoto, S.; Takashima, T.; Asano, Y.; Morisaki, T.; Kashiwagi, S.; Noda, S.; Onoda, N.; Ohira, M.; et al. Low Eosinophil Percentages as a New Predictive Marker for Infusion Reactions Due to Trastuzumab. Anticancer. Res. 2020, 40, 4047-4051.
Beer, L.A.; Kossenkov, A.V.; Liu, Q.; Prak, E.L.; Domchek, S.; Speicher, D.W.; Ky, B. Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction. Circ. Res. 2016, 119, 1135-1144.
Taweesedt, P.T.; Nordstrom, C.W.; Stoeckel, J.; Dumic, I. Pulmonary Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review. Biomed. Res. Int. 2019, 2019, 7863815.
Occhipinti, M.; Falcone, R.; Onesti, C.E.; Marchetti, P. Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report. Drug Saf. Case Rep. 2018, 5, 12.
Dehqanzada, Z.A.; Storrer, C.E.; Hueman, M.T.; Foley, R.J.; Harris, K.A.; Jama, Y.H.; Shriver, C.D.; Ponniah, S.; Peoples, G.E. Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology. Oncol. Rep. 2007, 17, 687-694.
Gonzalez, R.M.; Daly, D.S.; Tan, R.; Marks, J.R.; Zangar, R.C. Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased. Cancer Epidemiol. Biomark. Prev. 2011, 20, 1543-1551.
Lv, M.; Xiaoping, X.; Cai, H.; Li, D.; Wang, J.; Fu, X.; Yu, F.; Sun, M.; Lv, Z. Cytokines as prognstic tool in breast carcinoma. Front. Biosci. 2011, 16, 2515-2526.
Mortimer, J.E.; Waliany, S.; Dieli-Conwright, C.M.; Patel, S.K.; Hurria, A.; Chao, J.; Tiep, B.; Behrendt, C.E. Objective physical and mental markers of self-reported fatigue in women undergoing (neo)adjuvant chemotherapy for early-stage breast cancer. Cancer 2017, 123, 1810-1816.
Yu, L.R.; Cao, Z.; Makhoul, I.; Daniels, J.R.; Klimberg, S.; Wei, J.Y.; Bai, J.P.; Li, J.; Lathrop, J.T.; Beger, R.D.; et al. Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients. Exp. Biol. Med. 2018, 243, 248-255.
König, A.; Vilsmaier, T.; Rack, B.; Klaus Friese, K.; Janni, W.; Jeschke, U.; Andergassen, U.; Trapp, E.; Jückstock, J.; Jäge, B.; et al. Determination of Interleukin-4, -5, -6, -8 and -13 in Serum of Patients with Breast Cancer Before Treatment and its Correlation to Circulating Tumor Cells. Anticancer. Res. 2016, 36, 3123-3130. [PubMed]
Little, A.C.; Pathanjeli, P.; Wu, Z.; Bao, L.; Goo, L.E.; Yates, J.A.; Oliver, C.R.; Soellner, M.B.; Merajver, S.D. IL-4/IL-13 Stimulated Macrophages Enhance Breast Cancer Invasion via Rho-GTPase Regulation of Synergistic VEGF/CCL-18 Signaling. Front. Oncol. 2019, 9, 456.
Suzuki, A.; Leland, P.; Joshi, B.H.; Puri, R.K. Targeting of IL-4 and IL-13 receptors for cancer therapy. Cytokine 2015, 75, 79-88.
Onesti, C.E.J.C.; Boulet, D.; Bours, V.; Jerusalem, G. High Plasmatic level of IL-4 and IL-13 are associated with recurrence and worse survival in breast cancer. Tumori J. 2020, 106, 118.
Turner, M.C.; Chen, Y.; Krewski, D.; Ghadirian, P. An overview of the association between allergy and cancer. Int. J. Cancer 2006, 118, 3124-3132.
Vojtechova, P.; Martin, R.M. The association of atopic diseases with breast, prostate, and colorectal cancers: A meta-analysis. Cancer Causes Control 2009, 20, 1091-1105.
Bożek, A.; Jarzab, J.; Mielnik, M.; Bogacz, A.; Kozlowska, R.; Mangold, D. Can atopy have a protective effect against cancer? PLoS ONE 2020, 15, e0226950.
Kanda, A.; Yun, Y.; Bui, D.V.; Nguyen, L.M.; Kobayashi, Y.; Suzuki, K.; Mitani, A.; Sawada, S.; Hamada, S.; Asako, M.; et al. The multiple functions and subpopulations of eosinophils in tissues under steady-state and pathological conditions. Allergol. Int. 2021, 70, 9-18.
Prin, L.; Capron, M.; Tonnel, A.B.; Bletry, O.; Capron, A. Heterogeneity of human peripheral blood eosinophils: Variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophilia. Int. Arch. Allergy Appl. Immunol. 1983, 72, 336-346.
Mesnil, C.; Raulier, S.; Paulissen, G.; Xiao, X.; Birrell, M.A.; Pirottin, D.; Janss, T.; Starkl, P.; Ramery, E.; Henket, M.; et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J. Clin. Investig. 2016, 126, 3279-3295.
Johansson, M.W. Activation states of blood eosinophils in asthma. Clin. Exp. Allergy 2014, 44, 482-498.
Metcalfe, D.D.; Pawankar, R.; Ackerman, S.J.; Akin, C.; Clayton, F.; Falcone, F.H.; Gleich, G.J.; Irani, A.; Johansson, M.W.; Klion, A.D.; et al. Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organ. J. 2016, 9, 7.
Liu, L.Y.; Jarjour, N.N.; Busse, W.W.; Kelly, E.A.B. Chemokine receptor expression on human eosinophils from peripheral blood and bronchoalveolar lavage fluid after segmental antigen challenge. J. Allergy Clin. Immunol. 2003, 112, 556-562.
Liu, L.Y.; Sedgwick, J.B.; Bates, M.E.; Vrtis, R.F.; Gern, J.E.; Kita, H.; Jarjour, N.N.; Busse, W.W.; Kelly, E.A.B. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process. J. Immunol. 2002, 169, 6459-6466.
Mengelers, H.J.; Maikoe, T.; Hooibrink, B.; Kuypers, T.W.; Kreukniet, J.; Lammers, J.W.; Koenderman, L. Down modulation of L-Selectin expression on eosinophils recovered from bronchoalveolar lavage fluid after allergen provocation. Clin. Exp. Allergy 1993, 23, 196-204.
Hansel, T.T.; Braunstein, J.B.; Walker, C.; Blaser, K.; Bruijnzeel, P.L.; Virchow Jr, J.C.; Virchow Sr, C. Sputum eosinophils from asthmatics express ICAM-1 and HLA-DR. Clin. Exp. Immunol. 1991, 86, 271-277.
Hansel, T.T.; De Vries, I.J.; Carballido, J.M.; Braun, R.K.; Carballido-Perrig, N.; Rihs, S.; Blaser, K.; Walker, C. Induction and function of eosinophil intercellular adhesion molecule-1 and HLA-DR. J. Immunol. 1992, 149, 2130-2136.
Lucey, D.R.; Dorsky, D.I.; Nicholson-Weller, A.; Weller, P.F. Human eosinophils express CD4 protein and bind human immunodeficiency virus 1 gp120. J. Exp. Med. 1989, 169, 327-332.
Rand, T.H.; Silberstein, D.S.; Kornfeld, H.; Weller, P.F. Human eosinophils express functional interleukin 2 receptors. J. Clin. Investig. 1991, 88, 825-832.
Riedel, D.; Lindemann, A.; Brach, M.; Mertelsmann, R.; Herrmann, F. Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce surface expression of interleukin-2 receptor p55-chain and CD4 by human eosinophils. Immunology 1990, 70, 258-261. [PubMed]
Woerly, G.; Roger, N.; Loiseau, S.; Dombrowicz, D.; Capron, A.; Capron, M. Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): Inhibition by immunoglobulin a complexes. J. Exp. Med. 1999, 190, 487-495.
Rosenberg, H.F.; Domachowske, J.B. Eosinophils, ribonucleases and host defense: Solving the puzzle. Immunol. Res. 1999, 20, 261-274.